BTIG Starts Geron Corporation (GERN) at Neutral

August 19, 2016 8:31 AM EDT
Get Alerts GERN Hot Sheet
Price: $2.12 +1.44%

Rating Summary:
    5 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade GERN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BTIG initiated coverage on Geron Corporation (NASDAQ: GERN) with a Neutral rating.

Analyst Ling Wang said, "GERN’s flagship compound imetelstat, an inhibitor of telomerase partnered with Janssen (owned by JNJ, Neutral, Analyst: Dane Leone) showed impressive activity in myelofibrosis (MF) and myelodysplastic syndrome (MDS) in pilot studies. Although we are enthusiastic about imetelstat’s paradigm-changing potential, GERN is in a period of executing on two large trials in MF and MDS with a relatively thin data flow. We anticipate GERN shares to be range-bound until major data release, potentially in late 2017 or 2018."

For an analyst ratings summary and ratings history on Geron Corporation click here. For more ratings news on Geron Corporation click here.

Shares of Geron Corporation closed at $2.73 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

New Coverage

Related Entities


Add Your Comment